<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T09:43:27Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/47771" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/47771</identifier><datestamp>2026-05-15T19:49:47Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Marshall, Jocelyn Rose</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair">King, Michael R.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Lindau, Manfred</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Daniel, Susan</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2017-04-04T20:27:25Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2017-04-04T20:27:25Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2017-01-30</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 10050</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 10241028</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/47771</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/X4H41PFS</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">9906018</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Circulating tumor cells have been a major area of focus for cancer metastasis research for the last few decades, and while the majority of progress has mainly centered on the isolation and enumeration of CTC for prognostic purposes, researchers are beginning to explore additional uses for CTC in the clinical setting. While it is well known that CTC counts correlate with prognosis, CTC counts are also being explored as a marker for response to therapy. CTC enumerated before and after surgical procedures are shedding light on the advantages of minimally invasive techniques. 
CTC characterization has also increased in the past decade. When CTC were first reliably isolated, the majority of work focused solely on EpCAM-expressing cells found within the blood of patients with late stage cancer. Today, EpCAM-negative CTC and CTC expressing mesenchymal markers are under great scrutiny for a potentially increased metastatic potential. Moreover, CTC that differ in protein and gene expression to the primary tumor have been found elucidating prospective issues with drug targets. CTC have been isolated and identified in patients with local tumors or even pre-cancerous lesions. 
Here, we present a diagnostic method that uses CTC to prescreen for drug susceptibility. This method is then used to show primary CTC sensitivity to a novel TRAIL-based immunotherapeutic targeted towards CTC. Peripheral blood samples are shown to contain circulating stromal cells believed to migrate alongside CTC and likely alter their survival under shear conditions as well as their drug susceptibility. We culminate these studies by conducting the first efficacy study of EST liposomes in an immunocompetent breast cancer tumor resection murine model.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="rights" lang="*">Attribution-NonCommercial-ShareAlike 4.0 International</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri" lang="*">https://creativecommons.org/licenses/by-nc-sa/4.0/</dim:field>
   <dim:field mdschema="dc" element="subject">metastasis</dim:field>
   <dim:field mdschema="dc" element="subject">TRAIL</dim:field>
   <dim:field mdschema="dc" element="subject">Biomedical engineering</dim:field>
   <dim:field mdschema="dc" element="subject">E-selectin</dim:field>
   <dim:field mdschema="dc" element="subject">cancer</dim:field>
   <dim:field mdschema="dc" element="subject">cancer-associated fibroblast</dim:field>
   <dim:field mdschema="dc" element="subject">circulating tumor cell</dim:field>
   <dim:field mdschema="dc" element="title">Circulating Tumor Cells as Diagnostic Tools and Therapeutic Targets</dim:field>
   <dim:field mdschema="dc" element="type">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Biomedical Engineering</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Biomedical Engineering</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Marshall, Jocelyn Rose</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="7cb2713f-71cd-4ac4-84d7-f42ae11283d3">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en_US&lt;/Language>
   	&lt;Title>Circulating Tumor Cells as Diagnostic Tools and Therapeutic Targets&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2017-01-30&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/X4H41PFS&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Marshall, Jocelyn Rose&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>https://creativecommons.org/licenses/by-nc-sa/4.0/&lt;/License>
    &lt;Keyword>metastasis&lt;/Keyword>
    &lt;Keyword>TRAIL&lt;/Keyword>
    &lt;Keyword>Biomedical engineering&lt;/Keyword>
    &lt;Keyword>E-selectin&lt;/Keyword>
    &lt;Keyword>cancer&lt;/Keyword>
    &lt;Keyword>cancer-associated fibroblast&lt;/Keyword>
    &lt;Keyword>circulating tumor cell&lt;/Keyword>
   	&lt;Abstract>Circulating tumor cells have been a major area of focus for cancer metastasis research for the last few decades, and while the majority of progress has mainly centered on the isolation and enumeration of CTC for prognostic purposes, researchers are beginning to explore additional uses for CTC in the clinical setting. While it is well known that CTC counts correlate with prognosis, CTC counts are also being explored as a marker for response to therapy. CTC enumerated before and after surgical procedures are shedding light on the advantages of minimally invasive techniques. 
CTC characterization has also increased in the past decade. When CTC were first reliably isolated, the majority of work focused solely on EpCAM-expressing cells found within the blood of patients with late stage cancer. Today, EpCAM-negative CTC and CTC expressing mesenchymal markers are under great scrutiny for a potentially increased metastatic potential. Moreover, CTC that differ in protein and gene expression to the primary tumor have been found elucidating prospective issues with drug targets. CTC have been isolated and identified in patients with local tumors or even pre-cancerous lesions. 
Here, we present a diagnostic method that uses CTC to prescreen for drug susceptibility. This method is then used to show primary CTC sensitivity to a novel TRAIL-based immunotherapeutic targeted towards CTC. Peripheral blood samples are shown to contain circulating stromal cells believed to migrate alongside CTC and likely alter their survival under shear conditions as well as their drug susceptibility. We culminate these studies by conducting the first efficacy study of EST liposomes in an immunocompetent breast cancer tumor resection murine model.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>